Associations of GSTM1*0 and GSTA1*Agenotypes with the risk of cardiovascular death among hemodialyses patients by Sonja Suvakov et al.
Suvakov et al. BMC Nephrology 2014, 15:12
http://www.biomedcentral.com/1471-2369/15/12RESEARCH ARTICLE Open AccessAssociations of GSTM1*0 and GSTA1*A genotypes
with the risk of cardiovascular death among
hemodialyses patients
Sonja Suvakov1,9, Tatjana Damjanovic2, Tatjana Pekmezovic3,9, Jovana Jakovljevic4,9, Ana Savic-Radojevic1,9,
Marija Pljesa-Ercegovac1,9, Slavica Radovanovic5, Dragan V Simic6,9, Steva Pljesa7,9, Milos Zarkovic8,9,
Jasmina Mimic-Oka1,9, Nada Dimkovic2,9 and Tatjana Simic1,9*Abstract
Background: The presence of glutathione transferase (GST) M1 null genotype (GSTM1-null) in end-stage renal
disease (ESRD) patients is associated with lower overall survival rate in comparison to those with GSTM1-active
variants. We examined association between GSTM1 and GSTT1 deletion polymorphisms as well as SNPs in
GSTA1/rs3957357 and GSTP1/rs1695 genes with overall and cause-specific cardiovascular mortality in ESRD
patients.
Methods: Total of 199 patients undergoing hemodialysis were included in the study. Median value of time
elapsed from dialysis initiation until the death, or the end of follow-up was 8 ± 5 years. The effect of GSTM1,
GSTT1, GSTP1 and GSTA1 gene polymorphisms on predicting overall and specific cardiovascular outcomes
(myocardial infarction, MI or stroke) was analyzed using Cox regression model, and differences in survival were
determined by Kaplan-Meier.
Results: GSTM1-null genotype in ESRD patients was found to be independent predictor of overall and
cardiovascular mortality. However, after false discovery rate and Bonferroni corrections this effect was lost.
The borderline effect modification by wild-type GSTA1*A/*A genotype on associations between GSTM1-null and
analyzed outcomes was found only for death from stroke. Homozygous carriers of combined GSTM1*0/GSTA1*A
genotype exhibited significantly shorter time to death of stroke or MI in comparison with carriers of either GSTM1-active
or at least one GSTA1*B gene variant. The best survival rate regarding cardiovascular outcome was found for ESRD
patients with combined GSTM1-active and mutant GSTA1*B/*B genotype.
Conclusions: Combined GSTM1*0/GSTA1*A genotypes might be considered as genetic markers for cardiovascular
death risk in ESRD patients, which may permit targeting of preventive and early intervention.
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Oxidative stress in end stage renal disease (ESRD) pa-
tients is considered to be the cornerstone of atheroscler-
otic process. Carotid artery intima-media thickness in
chronic hemodialysis patients correlates with lipid per-
oxidation byproducts [1], while serum malondialdehyde* Correspondence: tatjanasimic@med.bg.ac.rs
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reproduction in any medium, provided the or(MDA) is a strong predictor of prevalent cardiovascular
disease in these patients [2]. Very recently it has been
shown that susceptibility to oxidative stress in ESRD is
influenced by the genetic polymorphism in antioxidant
and detoxifying enzymes glutathione transferases (GST).
The family of cytosolic GSTs comprises different classes
including the Alpha (GSTA), Mu (GSTM), Pi (GSTP)
and Theta (GSTT) class. Approximately half of the gen-
eral population lacks GSTM1 enzyme activity, due to a
homozygous deletion of the GSTM1 gene [3]. In the case
of GSTT1, gene homozygous deletion, present in aboutl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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activity [4]. Single-nucleotide polymorphism (SNP),
resulting in amino acid substitution from isoleucine (Ile)
to valine (Val) [5], changes catalytic activity of the
GSTP1 enzyme [6]. GSTA1 polymorphism is represented
by three, apparently linked, SNPs which result in differ-
ential expression with lower transcriptional activation of
the variant GSTA1*B (−567G, -69T, -52A) than common
GSTA1*A allele (−567T, -69C,-52G) [7]. According to
the presence of various GST gene variants in combin-
ation, ESRD patients may be stratified in level of oxida-
tive, carbonyl and nitrosative stress.
Since oxidative stress parameters correlate with car-
diovascular complications and mortality [8-11], inter-
action between the uremic state and particular GST
genotype would represent a potential mechanism
explaining the inter-individual differences in terms of
cardiovascular outcome in these patients. In the non-
ESRD population, individuals with GSTM1 and/or
GSTT1-null genotypes seem to be at higher risk of CVD
[12,13]. The observed link between GST polymorphism
and CVD was further strengthened in smokers lacking
GSTM1 or GSTT1 genes [14,15]. The GSTT1-null geno-
type and combined GSTT1*0/GSTM1*0 might be potential
determinants of susceptibility to advanced atherosclerosis
in patients with type 2 diabetes mellitus [16]. In ESRD pa-
tients, only polymorphic expression of GSTM1 was studied
with respect to prognostic significance. Although the pres-
ence of GSTM1-null genotype in ESRD patients was associ-
ated with lower overall survival compared to those with
GSTM1-active gene variants, specific association of this and
other common GST polymorphisms, with cause-specific
cardiovascular mortality still has to be addressed. This study
examined the association between the deletion polymor-
phisms in GSTM1 and GSTT1 as well as SNPs in GSTA1
(rs3957357) and GSTP1 (rs1695) genes with overall and
cardiovascular mortality as well as the death from myocar-




A total of 199 patients (84 male and 115 female, mean
age 60.0 ± 12.1 years) undergoing hemodialysis three
times a week were included in the study. All patients
were stable, aged over 21 and with HD vintage > 3
months before the study.
End stage renal failure was due to a hypertensive
nephrosclerosis (93), glomerulonephritis (32), diabetic
nephropathy (25), polycystic renal disease (19), pyelo-
nephritis (19), Balkan endemic nephropathy (7) and ob-
structive nephropathy in 4 patients. Patients were
treated with single-use dialyzers equipped with low flux
and high flux polysulphone membranes (surface area of1.3-2.1.m2). Study protocol was approved by the Belgrade
University Faculty of Medicine Ethic Committee and the
research was carried out in compliance with the Helsinki
Declaration. All the participants provided written in-
formed consent.
During 36 months cardiovascular mortality and all-
cause mortality were prospectively registered. Beginning
of the study is defined as time when patient started
chronic hemodialysis therapy. Information regarding
death and causes of death were obtained from hospital
records and other relevant documents. Causes of death
were classified as cardiovascular death if myocardial in-
farction and/or stroke occurred. Myocardial infarction
was diagnosed by cardiologist on the basis of clinical
presentation, ECG parameters and dynamic of enzyme
activities. Stroke was diagnosed by neurologist according
to clinical presentation and CT scan.
GST Genotyping
Genomic DNA was isolated from whole blood using the
QIAGEN QIAmp kit (Qiagen, Inc., Chatsworth, CA).
GSTA1 C-69T polymorphism was determined by poly-
merase chain reaction–restriction fragment length poly-
morphism (PCR-RFLP) [17]. Used primers were GSTA1
C-69T forward: 5′-TGTTGATTGTTTGCCTGAAATT-
3′ and GSTA1 C-69T reverse, 5′-GTTAAACGCTGT-
CACCCGTCCT-3′. Presence of restriction site resulting
in two fragments (481bp and 385bp) indicated mutant
allele (GSTA1*B/B) and if GSTA1*A/B polymorphism in-
curred it resulted in one more fragment of 96bp.
GSTM1 genotyping was performed by multiplex PCR
[17]. Used primers were GSTM1 forward: 5′-GAACTC
CCTGAAAAGCTAAAGC-3′ and GSTM1 reverse: 5′-GT
TGGGCTCAAATATACGGTGG-3′. Exon 7 of CYP1A1
gene was co-amplified and used as an internal control
using following primers: CYP1A1 forward: 5′-GAACT
GCCACTTCAGCTGTCT-3′ and CYP1A1 reverse: 5′-C
AGCTGCATTTGGAAGTGCTC-3′. The presence of
GSTM1-active genotype was detected by the band at
215bp, since the assay does not distinguish heterozygous
or homozygous wild type genotypes.
GSTP1 Ile105Val polymorphism was analyzed using
PCR-RFLP method [17]. Used primers were: GSTP1
Ile105Val forward: 5′-ACCCCAGGGCTCTATGGGAA-3′
and GSTP1 Ile105Val reverse: 5′-TGAGGGCACAAGAAG
CCCCT-3′. Presence of restriction site resulting in two
fragments (91bp and 85bp) indicated mutant allele
(Val/Val) while if Ile/Val polymorphism incurred it resulted
in one more fragment of 176bp.
GSTT1 genotyping was performed by multiplex
PCR [17]. Used primers were GSTT1-forward: 5′-
TTCCTTACTGGTCCTCACATCTC-3′ and GSTT1-
reverse: 5′-TCACGGGATCATGGCCAGCA-3′. The
assay does not distinguish between heterozygous or
Table 1 Baseline characteristics of patients with ESRD
Variable ESRD patients








Current + Former 54 (27.1)
Never 142 (71.4)
BMI (kg/m2) 24.5
Total cholesterol (mmol/L) 4.7 ± 1.1
Urea (mmol/L) 24.4 ± 4.8
Creatinine (μmol/L) 880.2 ± 238.6















aActive (present) if at least one active allele present. bInactive (null) if no active
alleles present.
*x ± SD.
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ence of 480bp bands was indicative for GSTT1-active
genotype.
Statistical analysis
Survival analysis was performed separately in the total
cohort and according to the cardiovascular cause of
death. The Kaplan-Meier method was used to estimate
the cumulative survival probability. We defined the ini-
tiation of dialysis as a zero time and the death as the
end-point. The long-rank test was performed for the
assessment of differences in survival according to the
different categories of variables.
The predictive value of different GST genotypes in
overall and cardiovascular mortality was assessed by Cox
proportional hazards regression models, adjusted by
confounding factors in three models. The numbers of
patients included in regression models were the same
for the all tested GST polymorphisms. For overall mor-
tality, the number of patients included in Model 1, 2 and
3 were 186, 183 and 169, respectively; for cardiovascular
mortality 180, 177 and 166 patients, respectively; for
myocardial infarction 189, 186 and 169 patients and for
cardiovascular insult 190, 187 and 169 patients, respect-
ively. In Model 1 we adjusted for age and gender. Model
2 included the covariates in Model 1 plus an additional
adjustment for the current smoking status. Model 3 in-
cluded all covariates from Models 1 and 2, plus an add-
itional adjustment for diabetes and cholesterol status.
The associations are presented as hazard ratios (HR)
with their corresponding 95% confidence intervals (95%
CI). To control for multiple comparisons we used mult-
test package in R. We reported corrected p values ob-
tained by methods that control family-wise error rate
[18] and false discovery rate [19,20].
Results
Table 1 describes the baseline characteristics of the 199
dialysis patients in this study. Time elapsed from dialysis
initiation until the death, or the end of follow up, ranged
from one to 27 years, with a median value of 8 ± 5 years.
There were 55 deaths during the follow-up. The causes
of death among our study cohort included cardiovascu-
lar diseases (n = 36), infection and sepsis (n = 10), neo-
plasm (n = 4), gastrointestinal bleeding (n = 2), chronic
obstructive lung disease (n = 1), and cachexia (n = 2).
Both myocardial infarction and stroke were causes of
death in 6 patients. The cause of death was unknown in
2 patients. Although the genotype distribution has been
already presented in our previous report [17], herein we
place the genotype distribution among ESRD patients in
order to better describe of our cohort.
Table 2 summarizes the associations between GSTM1
polymorphism and overall, cardiovascular mortality aswell as the death of myocardial infarction and stroke.
Multivariable Cox regression analysis was used to deter-
mine the independent effect of GST gene polymorphisms
on predicting these outcomes and included five other
variables (age, gender, current smoking status, presence
of diabetes, and cholesterol level) in three models
(Table 2). The presence of the GSTM1-null genotype
was an independent predictor of a higher risk for overall
and cardiovascular mortality among MHD patients. This
genotype had a significant multivariable adjusted (Model 3)
HR of 2.08 (CI:1.10-3.92; p = 0.024) and 2.19 (CI:1.00-4.79;
p = 0.050) for both overall and cardiovascular mortality,
respectively. Moreover, GSTM1-null genotype was a strong
independent predictor of CVI death with multivariable
adjusted (Model 3) HR of 3.80 (CI:1.03-14.02; p = 0.045).
However, after multiple testing (Additional file 1: Table S3)
Table 2 GSTM1 polymorphism as a predictor for overall and cardiovascular mortality as well as death of myocardial
infarction and cerebral vascular insult among 199 ESRD patients after a median follow-up time of 8 yrs by Cox
proportional hazards regression models
Model 1a Model 2b Model 3c
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Risk for overall mortality comparing GSTM1-null homozygotes to GSTM1-active carriers
1.74 (0.96-3.14) 0.066 1.88 (1.03-3.45) 0.041 2.08 (1.10-3.92) 0.024
Risk for cardiovascular mortality comparing GSTM1-null homozygotes to GSTM- active carriers
1.96 (0.95-4.08) 0.070 2.03 (0.97-4.22) 0.060 2.19 (1.01-4.79) 0.050
Risk for death from myocardial infarction comparing GSTM1-null homozygotes to GSTM1-active carriers
1.70 (0.65-4.49) 0.281 1.74 (0.66-4.60) 0.263 1.82 (0.63-5.26) 0.270
Risk for death from CVI comparing GSTM1-null homozygotes to GSTM1-active carriers
3.38 (0.96-11.94) 0.058 3.54 (0.99-12.56) 0.051 3.80 (1.03-14.02) 0.045
Abbreviations: CI Confidence Interval, HR Hazard Ratio.
aAdjusted for age and gender.
bAdjusted for the covariates in Model 1 plus an additional adjustment for smoking status.
cAdjusted for the covariates in Model 2 plus an additional adjustment for diabetes and cholesterol level.
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survival analysis demonstrated shorter overall (Log Rank:
p = 0.059) and cardiovascular survival (Log Rank: p = 0.043)
as well as shorter time to death of MI (Log Rank: p = 0.235)
or stroke (Log Rank: p = 0.038) after the initiation of dialysis
in patients who were homozygous for GSTM1-null alleles
in comparison with carriers of at least one active GSTM1
allele (Figure 1).
Table 3 summarizes the association between GSTA1
polymorphism with overall and cardiovascular mortality
as well as the death of myocardial infarction and stroke.
Multivariable adjusted (age, gender, current smoking sta-
tus, presence of diabetes, and cholesterol level, Model 3)
Cox regression analysis has shown the lack of associ-
ation between GSTA1 polymorphism and overall mortal-
ity (HR = 1.15; 95% CI:0.64-2.07; p = 0.650). However,
patients homozygous for GSTA1*A allele demonstrated a
non-statistically significant HRs of 1.73, 1.87 and 2.52
for cardiovascular mortality, MI and stroke, respectively. A
Kaplan-Meier survival analysis demonstrated shorter, but
non-significant overall (Log Rank: p = 0.429) and cardiovas-
cular survival (Log Rank: p = 0.303) as well as shorter time
to death of MI (Log Rank: p = 0.209) or stroke (Log Rank:
p = 0.291) after the initiation of dialysis in patients who
were homozygous for GSTA1*A alleles compared to car-
riers of at least one GSTA1*B allele (Figure 2).
There were no robust statistical associations between
GSTP1 and GSTT1 gene variants with overall, cardiovas-
cular mortality as well as the death of myocardial infarc-
tion and stroke in dialysis patients according to Cox
regression analysis (Additional file 2: Table S1 and
Additional file 3: Table S2).
Interactive effects between GSTM1*0/0 and the
GSTA1*A/A genotypes on the risk of various outcomes
in ESRD patients are presented in Table 4. Regarding therisk for overall or cardiovascular mortality Cox regres-
sion analysis did not show interactive effects between
GSTM1 and GSTA1 polymorphisms. However, patients
with combined GSTM1-null and GSTA1*A/*A genotype
exhibited a higher, although, non-significant multivari-
able adjusted (Model 3) HR of 2.27 (95% CI:0.81-6.38,
P = 0.121) for MI, compared to individual polymor-
phisms (Table 4). Moreover, statistically significant inter-
active effect existed between GSTM1-null and the
GSTA1*A/*A genotype for death of stroke. Specifically,
dialysis patients who were homozygous for both
GSTM1*0 and GSTA1*A alleles exhibited a HR of 4.38
(95%CI:1.50-12.75, P = 0.007) for stroke in comparison with
carriers of at least one GSTM1-active and/or GSTA1*B al-
lele. However after multiple testing (Additional file 1: Tables
S3A and S3B and Additional file 4: Table S4) none of
models remained significant. Additionally, in controlling for
multiple testing, we excluded tests for GSTM1 and GSTA1
genes as they are marginal to GSTM1/GSTA1 interaction.
A Kaplan-Meier survival analysis showed a significant asso-
ciation of combined GSTM1 and GSTA1 polymorphisms
on ESRD patients survival (Figure 3). Namely, this analysis
demonstrated a significantly shorter overall (Log Rank: p =
0.018) and cardiovascular survival (Log Rank: p = 0.052) as
well as shorter time to death of MI (Log Rank: p = 0.159)
or stroke (Log Rank: p = 0.027) after the initiation of dialy-
sis in patients with combinedGSTM1*0/0 and GSTA1*A/A
genotype in comparison with carriers of at least one
GSTM1-active or GSTA1*B allele (Figure 3). Patients with
combined GSTM1-active and GSTA1*B/B genotype had
the best survival rate (Figure 3).
Discussion
The data obtained in this study have shown that
GSTM1-null genotype in ESRD patients is a significant
Table 3 GSTA1 polymorphism (rs3957357) as a predictor for overall and cardiovascular mortality as well as death of
myocardial infarction and cerebral vascular insult among 199 ESRD patients after a median follow-up time of 8 yrs by
Cox proportional hazards regression models
Model 1a Model 2b Model 3c
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Risk for overall mortality comparing GSTA1*A homozygotes to GSTA1*B carriers
1.18 (0.68-2.07) 0.556 1.15 (0.65-2.02) 0.635 1.15 (0.64-2.07) 0.650
Risk for cardiovascular mortality comparing GSTA1*A homozygotes to GSTA1*B carriers
1.56 (0.80-3.04) 0.194 1.59 (0.81-3.11) 0.177 1.73 (0.84-3.55) 0.134
Risk for death from myocardial infarction comparing GSTA1*A homozygotes to GSTA1*B carriers
1.70 (0.68-4.29) 0.259 1.72 (0.68-4.36) 0.255 1.87 (0.68-5.15) 0.228
Risk for death from CVI comparing GSTA1*A homozygotes to GSTA1*B carriers
2.25 (0.81-6.21) 0.119 2.32 (0.83-6.46) 0.107 2.52 (0.86-7.36) 0.091
Abbreviations: CI Confidence Interval, HR Hazard Ratio, CVI Cerebral Vascular Insult.
aAdjusted for age and gender.
bAdjusted for the covariates in Model 1 plus an additional adjustment for smoking status.
cAdjusted for the covariates in Model 2 plus an additional adjustment for diabetes and cholesterol level.
Figure 1 Kaplan Meier Survival Curves for overall and cardiovascular mortality as well as death of myocardial infarction (MI) and
stroke according to GSTM1 polymorphism.
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Table 4 Combined effect of GSTM1/GSTA1 polymorphisms as predictors for overall and cardiovascular mortality as
well as death of myocardial infarction and cerebral vascular insult among 199 ESRD patients after a median follow-up
time of 8 yrs by Cox proportional hazards regression models
Model 1a Model 2b Model 3c
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Risk for overall mortality comparing combined GSTM1*0/0 and GSTA1*A/A homozygotes to carriers of at least one GSTM1-active and/or
GSTA1*B allele
1.86 (1.03-3.36) 0.039 1.98 (1.10-3.58) 0.023 2.08 (1.13-3.83) 0.019
Risk for cardiovascular mortality comparing combined GSTM1*0/0 and GSTA1*A/A homozygotes to carriers of at least one GSTM1-active
and/or GSTA1*B allele
1.88 (0.93-3.82) 0.078 1.92 (0.95-3.91) 0.070 2.06 (0.98-4.34) 0.057
Risk for death of MI comparing combined GSTM1*0/0 and GSTA1*A/A homozygotes to carriers of at least one GSTM1-active and/or
GSTA1*B allele
2.23 (0.86-5.80) 0.099 2.25 (0.86-5.89) 0.098 2.27 (0.81-6.38) 0.121
Risk for death of CVI comparing combined GSTM1*0/0 and GSTA1*A/A homozygotes to carriers of at least one GSTM1 active and/or
GSTA1*B allele
3.35 (1.22-9.21) 0.019 3.55 (1.28-9.84) 0.015 4.38 (1.50-12.75) 0.007
Abbreviations: CI Confidence Interval, HR Hazard Ratio, CVI Cerebral Vascular Insult, MI Myocardial Infarction.
aAdjusted for age and gender.
bAdjusted for the covariates in Model 1 plus an additional adjustment for smoking status.
cAdjusted for the covariates in Model 2 plus an additional adjustment for diabetes and cholesterol level.
Figure 2 Kaplan Meier Survival Curves for overall and cardiovascular mortality as well as death of myocardial infarction (MI) and
stroke according to GSTA1 polymorphism.
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Figure 3 Kaplan Meier Survival Curves for overall and cardiovascular mortality as well as death of myocardial infarction (MI) and
stroke according to combined effect of GSTM1/GSTA1 polymorphisms.
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mortality. Besides, homozygous carriers of wild type
GSTA1*A allele exhibited an increased risk of cardiovas-
cular death, specifically MI and stroke, although the
observed HR did not reach statistical significance in
various models tested. The significant effect modifica-
tion by GSTA1*A/A genotype on associations between
GSTM1-null and analyzed outcomes was found only
for the death from stroke. Homozygous carriers of com-
bined GSTM1*0/GSTA1*A genotype exhibited significantly
shorter time to MI or stroke in comparison to ESRD pa-
tients carriers of either GSTM1-active or GSTA1*B gene
variant. The best survival rate in terms of cardiovascular
outcome was found for ESRD patients with combined
GSTM1-active and mutant GSTA1*B/B genotype.
Several lines of evidence indicate an association be-
tween the GSTM1*0/0 genotype and faster progression
of kidney disease as well as worse outcome of dialysis
patients. Very recently Chang et al. [21] have shown that
GSTM1-null allele influences the course of kidney dis-
ease progression in participants of the African AmericanStudy of Kidney Disease (AASK) trial. Patient groups
with and without the common GSTM1-null allele, dif-
fered significantly in the time to a glomerular filtration
rate event or dialysis, or death. Similarly, Lin et al. [8]
showed that dialysis patients with the GSTM1*0/0 geno-
type exhibit higher mortality rate when compared to
those with the active enzyme. Our results confirmed
these findings regarding the deleterious effect of
GSTM1*0/0 genotype on overall mortality in ESRD pa-
tients. Furthermore, by the cause-specific analysis of the
association between GSTM1 and cardiovascular causes
of death, such as MI and stroke, we provided a direct
proof of the role of GSTM1 protein in prevention of oxi-
dative stress related cardiovascular complications.
Namely, patients lacking GSTM1 protein (GSTM1*0/0
genotype) demonstrated a significantly higher risk of
cardiovascular death. When ESRD patients were further
stratified according to the specific cause of death (MI or
stroke), Kaplan Meier analysis demonstrated a signifi-
cantly shorter time to death from both cardiovascular
causes in patients with GSTM1*0/0 genotype in
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pendent significant association between GSTM1*0/0
genotype remained only for the death from stroke as
shown by Cox regression analysis. To our knowledge this
is the first report showing a significant association be-
tween GSTM1-null genotype and the death from stroke in
ESRD patients. These results are biologically plausible
given the role of GSTM1 in antioxidant protection and
the progression of carotid atherosclerosis in pro-oxidant
environment. Oxidized lipids are GST substrates while
GSTM1 directly regulates intracellular levels of lipid per-
oxidation by product 4-hydroxynonenal (4-HNE) in vas-
cular smooth muscle cells [18]. A prospective study in
Netherlands confirmed an increased progression of athero-
sclerosis among smokers lacking the enzyme GSTM1 [22].
Specifically, de Waart et al. demonstrated that the male
smokers with the GSTM1 genotype had a higher mean 2-yr
progression of the common carotid artery intima-media
thickness compared to those with GSTM1 [22]. Although
in this study we did not address the progression of carotid
atherosclerosis in relation to GSTM1 genotype, it may be
speculated that the deleterious effect of GSTM1-null geno-
type might be even more pronounced in ESRD patients
than in smokers, because of their higher exposure to
dialysis-related oxidant stress. Having in mind that in
chronic kidney disease the GSTM1 is normally up-
regulated in a protective response to increased oxidative
stress, as well as that the GSTM1 could be a surrogate for
unmeasured oxidative stress markers [17,23], it seems rea-
sonable to assume that this genetic variant may be deleteri-
ous in terms of carotid atherosclerosis and consequent
stroke in ESRD patients.
The question arises about the association between
GSTM1-null genotype and death from myocardial in-
farction being weaker than that observed for stroke. A
recent meta-analysis suggested that the GSTM1*0/0
genotype associated with an increased risk of ischemic
heart disease (OR, 1.38; 95% CI, 1.01 to 1.87) [24,25]. Al-
though the presence of double deletion genotypes of the
GSTM1 gene is associated with hypertriglyceridemia and
low HDL-cholesterol levels in healthy humans [26], it
has not been shown directly that the null alleles actually
change cardiac or coronary vascular GST activity. As-
suming a change in activity, we cannot exclude a com-
pensatory increase in expression of other GSTs in
myocardium of M1-null genotypes in condition of dialy-
sis related oxidative stress. Unlike humans, mice and rats
do not possess the GST-null genotypes. However, genetic
variation in expression of Gstm1 in mice has been asso-
ciated with differences in vascular smooth muscle cell
proliferation, reactive oxygen species production, and
cell migration in one study [27]. Updated meta-analyses
of risk of IHD as a function of GSTM1*0/0 and
GSTT1*0/0 genotypes in all studies combined, did notshow an association of GST*0/0 genotype with the risk
of ischemic heart disease, with the exception of GSTM1
[28]. These results are in line with the lack of association
of double deletion in GSTT1 genotype and cardiovascu-
lar death risk in our cohort of ESRD patients.
Interestingly, in this study we found effect modifica-
tion for the association between GSTM1*0/0 genotype
and cardiovascular mortality by GSTA1*A/A genotype,
which is associated with higher transcriptional activity
and consequent higher levels of GSTA1 enzyme. This re-
sult was unexpected since in several non-malignant dis-
eases GSTA1*B allele with lower transcriptional activity
was associated with increased risk. Thus in Japanese,
GSTA1*B allele is a potential risk factor for smoking-
related type 2 diabetes and hypertension [29]. The inter-
pretation of our results on effect modification by
GSTA1*A/A genotype in GSTM1*0/0 individuals regard-
ing the death from MI and stroke should be in the light
of the fact that ESRD patients exhibit powerful oxidant
stress, and therefore a strong Nrf mediated induction of
GST expression [30]. GSTA1 protein belongs to the
most promiscuous GSTs that acts upon a broad range of
substrates which bind to its active site [31-33]. However,
conjugation with GSH by means of GST enzymes some-
times results in the formation of more reactive com-
pounds [34-36]. It may be speculated that some of the
accumulated uremic toxins is converted into more react-
ive intermediates by GSTA1 protein. Although such an
assumption still has to be documented, ESRD is not the
only a disease in which GSTA1*A allele confers an in-
creased risk. Namely, homozygous wild-type GSTA1
genotype is associated with an increased risk of gastric
cancer in Vietnamese patients [37].
Taken together, our data suggest that GSTM1*0/0
genotype and GSTM1*0/GSTA1*A genotype are the risk
factors for cardiovascular death in ESRD patients, al-
though after multiple testing our models missed statis-
tical significance. These genetic markers may permit the
targeting of preventive and early intervention on high-
risk patients to reduce their cardiovascular risk. Specific-
ally, studies are needed to reliably assess the effects of
antioxidant therapy in people with GSTM1*0/0 geno-
type. In accordance with our previous findings these
data suggest that the patients with GSTM1*0/0 genotype
represent potential candidates for antioxidant therapy
with the aim of stroke prevention. Although the antioxi-
dant therapy does not reduce the risk of cardiovascular
and all-cause death or major cardiovascular events in
people with chronic kidney disease, according to the lat-
est systematic review and metaanalysis [38,39] it is pos-
sible that some patients with particular genetic milieu
may have a benefit from such therapy.
Certain limitations could be considered in our study.
Relatively small numbers of both study participants and
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http://www.biomedcentral.com/1471-2369/15/12GST polymorphisms studied might be sources of poten-
tial biases which may influence the study findings. For-
mal power calculation revealed a 1-beta = 0.68. However,
we tested effects of four GST polymorphisms on differ-
ent treatment outcomes in 199 ESRD patients and there-
fore significantly decreased a chance for publication bias.
Namely, positive results of genetic studies analyzing a
small number of polymorphisms (n = 1-3) should be
evaluated cautiously and considered at a lower level of
evidence [40]. Another important point in our study is
the low number of events (55 deaths, 36 of which due to
cardiovascular causes) which may influence definitive
conclusions about relationships between the polymor-
phisms and some relevant clinical outcomes. Addition-
ally, after multiple testing none of models remained
significant. Besides that, survival bias could be present
due to the fact that an increased hazard for cardiovascu-
lar events in the chronic kidney disease patients may
contribute to the death of these persons prior to reaching
dialysis and consequently to the under-representation of the
polymorphism effects in our cohort. Therefore the results of
our study require validation in other dialysis cohorts.Conclusion
In conclusion, combined GSTM1*0/GSTA1*A genotypes
might be considered as genetic markers for cardiovascu-
lar death risk in ESRD patients, which may permit tar-
geting of preventive and early intervention. Based on
our results, it can be assumed that patients with particu-
lar genetic milieu might have a benefit from antioxidant
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